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Abstract Chromosomal amplifications are among the
most common genetic alterations found in human cancers.
However, experimental systems to study the processes that
lead to specific, recurrent amplification events in human
cancers are lacking. Moreover, some common amplifica-
tions, such as that at 8p11-12 in breast cancer, harbor
multiple driver oncogenes, which are poorly modeled by
conventional overexpression approaches. We sought to
develop an experimental system to model recurrent chro-
mosomal amplification events in human cell lines. Our
strategy is to use homologous-recombination-mediated
gene targeting to deliver a dominantly selectable, amplifi-
able marker to a specified chromosomal location. We used
adeno-associated virus vectors to target human MCF-7
breast cancer cells at the ZNF703 locus, in the recurrent
8p11-12 amplicon, using the E. coli inosine monophos-
phate dehydrogenase (IMPDH) enzyme as a marker. We
applied selective pressure using IMPDH inhibitors. Sur-
viving clones were found to have increased copy number of
ZNF703 (average 2.5-fold increase) by droplet digital PCR
and FISH. Genome-wide array comparative genomic
hybridization confirmed that amplifications had occurred
on the short arm of chromosome 8, without changes on 8q
or other chromosomes. Patterns of amplification were
variable and similar to those seen in primary human breast
cancers, including ‘‘sawtooth’’ patterns, distal copy number
loss, and large continuous regions of copy number gain.
This system will allow study of the cis- and trans-acting
factors that are permissive for chromosomal amplification
and provide a model to analyze oncogene cooperativity in
amplifications harboring multiple candidate driver genes.
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Introduction
Chromosomal amplifications are a major type of genetic
aberration found in human cancers of many histologies [1].
The importance of chromosomal amplifications to tumor
biology is exemplified by the ERBB2/HER-2 amplification
in 15–20 % of breast cancers [2]. Identification of this
amplification was initially shown to be a poor prognostic
feature. Subsequently molecular genetic analysis identified
the HER-2 gene as a major oncogenic driver in the
amplicon, which has been subsequently targeted for ther-
apy with great success in the clinic. Chromosomal ampli-
fication of the dihydrofolate reductase (DHFR) gene was
initially described as a mechanism of resistance to the
chemotherapeutic drug methotrexate, and there are recent
examples of acquired resistance to epidermal growth factor
receptor tyrosine kinase inhibitors for lung cancer via MET
amplification [3, 4]. Thus, chromosomal amplification
plays a key role in cancer origination and therapeutic
response.
Much of our knowledge of chromosomal amplification
derives from studies in model organisms such as yeast or
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from experimental amplification of the endogenous DHFR
locus. Stepwise increases in methotrexate concentration in
culture can lead to amplification of the endogenous DHFR
locus or a DHFR-linked transgene in rodent and some
human cell lines [3, 5–8]. Random insertion of a mutant
DHFR transgene in HCT-116 ? chr3 colon cancer cells
was used with methotrexate selection to amplify insertion
sites and surrounding genomic loci [9].
Some recurrent amplifications in human cancers occur
near the so-called DNA fragile sites, which are prone to
spontaneous DNA breakage under conditions of replication
stress, but the mechanisms underlying recurrent amplifi-
cation at many loci remain poorly understood [10, 11]. We
hypothesize that there are likely locus and cell-type-
specific differences in terms of susceptibility to chromo-
somal amplification and that it would be useful to be able
to study amplification of a greater variety of loci beyond
DHFR. While genetic engineering has enabled modeling of
specific mutations, deletions, and chromosomal transloca-
tions found in human cancer, we are not aware of a method
for engineering specific, rather than random, chromosomal
amplification events. We have developed such a method
and as a proof of principle have engineered a recurrent
amplification found in human breast cancers in a human
breast cancer cell line.
Materials and methods
Cell lines
MCF-7 and MDA-MB-134VI cells were obtained from
ATCC. Identity of MCF-7 cells was verified by sequencing
for the described PIK3CA and GATA3 mutations, as well as
by identification of described chromosomal amplifications
by comparative genomic hybridization. Parental MCF-7
cells and their derivatives were maintained in DMEM
4.5 g/dL glucose (Invitrogen) supplemented with 5 % FBS
and 100 U/mL penicillin and 100 lg/mL streptomycin
(Invitrogen). Targeted 38C-3 cells were maintained in the
above medium supplemented with 10 lM mycophenolic
acid (MPA) (Sigma). Amplified subclones were selected
and maintained in the above medium supplemented with
10 lM MPA and 10 lM mizoribine (Sigma). MDA-MB-
134VI cells were grown in DMEM with 10 % FBS and
penicillin/streptomycin as above. All cells were cultured at
37 C at 5 % CO2.
Gene targeting of the ZNF703 locus
The SEPT targeting vector has been described [12]. The
neomycin resistance cassette was replaced with an insert
containing the E. coli inosine monophosphate
dehydrogenase (IMPDH) cDNA, which was PCR amplified
from Top10F E. coli cells (Invitrogen). The IMPDH insert
was cloned downstream of the IRES sequence and
upstream of the polyadenylation signal in SEPT. 50- and 30-
homology arms targeting the ZNF703 locus were con-
structed by PCR using genomic DNA from MCF-7 as
template for the homology arms. Primer sequences are
shown in Supplementary Table 1. Recombinant AAV
production and infection were performed as described [13,
14]. MCF-7 cells were selected in 10 lM MPA in 96-well
plates. Surviving colonies were screened for homologous
targeting of the cassette using a pooling strategy and PCR
as described [15]. Positive colonies were re-cloned by
limiting dilution and re-screened to ensure homogeneity.
Amplification drug selection
Targeted 38C-3 cells were plated at 4000 cells per well in a
96-well plate in medium containing 10 lM MPA and
10 lM mizoribine (Sigma). After approximately 4 weeks,
resistant colonies were identified and expanded.
DNA and RNA extraction, cDNA synthesis,
and PCR
Genomic DNA and total RNA were prepared from cells
using QIAamp DNA Blood kits and RNeasy kits (Qiagen),
respectively. cDNA was synthesized with First-Strand
cDNA Synthesis kits (GE Biosciences). PCR amplification
was performed with a GeneAmp 9700 (Applied Biosys-
tems) and Phusion Hot Start II polymerase (NEB). qRT-
PCR was performed on cDNA with forward and reverse
primers located in distinct exons on an iCycler machine
(Bio Rad) using Platinum Taq polymerase (Invitrogen) and
SYBR Green dye (Invitrogen). Primer sequences for RT-
PCR are in Supplementary Table 1.
Droplet digital PCR
TaqMan Primer/probe sets for ZNF703 (FAM-label) and the
reference gene RPP30 (VIC-label) were obtained from Life
Technologies. ddPCR was performed as described [16].
Genomic DNAwas digested with Mse I. Eight ng of digested
gDNA was mixed with ddPCR supermix (Bio Rad) and one
microliter each of the ZNF703 and RPP30 primer/probe
mixes. Twentymicroliters of this mixture was combined with
70 microliters of droplet generator oil and emulsified in a
droplet generator (Bio Rad). Thirty-nine microliters of this
sample was transferred to a PCR plate and amplified using
conditions as described [16], and droplets were read for flu-
orescence using a Bio Rad QX100 droplet reader. Results
were analyzed using QuantaSoft software (Bio Rad) to nor-
malize copy number relative to RPP30.
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Array CGH
RNAase A-treated genomic DNA from parental MCF-7
cells, 38C-3 cells, and subclones E8, F3, and G5 was
labeled and hybridized to Agilent 4 9 180 K arrays using
normal human female genomic DNA as a control,
according to the manufacturer’s instructions (Agilent
Technologies, Santa Clara, CA). Data were extracted using
Feature Extraction Software v9.1 (Agilent Technologies),
and visualization was performed using Agilent Genomic
Workbench v.7.0 using the hg19 version of the human
genome as a reference. Hybridization and data acquisition
and processing was performed at the Johns Hopkins
SKCCC Microarray Core facility.
FISH
Cells were seeded in 8-well chamber slides, fixed overnight
in a 10 % neutral buffered formalin solution and allowed to
dry. Slides were then treated with 2 N HCl for 20 min,
Vysis Pretreatment Kit I (Abbott Molecular), washed with
a 2 9 SSC buffer, and incubated in pretreatment buffer at
80 C for 30 min. Slides were rinsed with dH2O and
washed with 2x SSC buffer, placed in Vysis protease buffer
(Abbott Molecular) at 37 C for 8 min, washed with 2x
SSC buffer, and fixed in 10 % neutral buffered formalin for
10 min. Slides were then dehydrated with ethanol baths
and kept at room temperature for up to 2 weeks. Samples
were hybridized with probes at 95 C for 5 min and
incubated at 37 C for 48 h, treated with a 0.3 % NP-40 at
75 C, counter-stained with DAPI (1:10,000) and sealed
with Prolong Gold (Invitrogen). Samples were imaged
using a Nikon fluorescence microscope and NIS-Elements
BR 2.30 imaging program. FISH probes pre-labeled with
fluorophores were to centromeric sequence of chromosome
8 (Abbott Molecular) or BAC probes to FGFR1, ZNF703
(RPCI-11-101H15), NRG1 (RPCI-11-15H14) (Empire
Genomics).
Immunoblotting
Whole-cell protein extracts prepared in Laemmli sample
buffer were resolved by SDS-PAGE using NuPage 4–12 %
gels (Invitrogen), transferred to Invitrolon polyvinylidene
difluoride membranes (Invitrogen), and probed with pri-
mary and horseradish peroxidase-conjugated secondary
antibodies. Primary antibodies to RAB11FIP1 (#9438),
ASH2L (#5019), FGFR1 (#9740), and GAPDH (#5174)
were from Cell Signaling Technologies. ZNF703 antibody
was from GeneTex (#107721). Blots were exposed to
Kodak XAR film using chemiluminescence for detection
(Perkin Elmer).
Results
A strategy to engineer site-specific chromosomal
amplifications
Model systems for gene amplification have generally relied
on dominantly selectable enzymes such as DHFR and CAD
[3, 17]. Cells expressing the enzyme are treated with an
inhibitor, such as methotrexate or PALA, respectively,
selecting for a subset of surviving cells with increased
expression of the enzyme. In some cases, the increase in
enzyme expression is caused by increased copy number of
the locus encoding the enzyme. We reasoned that targeting
such an amplifiable selectable marker to a genomic locus of
our choice could lead to subsequent amplification of that
locus and surrounding sequences under selective pressure
from an inhibitor. We re-designed a recombinant adeno-
associated virus (AAV) gene targeting vector for this
purpose (Fig. 1; [12]). Since we did not wish to disrupt the
coding sequence of our targeted gene, we designed
homology arms targeting the selection cassette to the 30
UTR of the chosen gene, downstream of the stop codon but
upstream of the endogenous polyadenylation signal.
In order to avoid first having to generate a cell line null
for the enzyme we planned to employ for amplification
selection, we wished to use a dominantly selectable mar-
ker, i.e., one which we could select in the presence of the
endogenous cellular genes. Such a marker must have a
differential sensitivity to available enzyme inhibitors. We
chose E. coli IMPDH. IMPDH is a rate limiting step in de
novo synthesis of GTP. E. coli IMPDH has been shown
previously to function as a dominant selectable marker in
various human cell lines, as it is resistant to the inhibitor
MPA, which effectively inhibits the endogenous human
IMPDH enzymes [18]. Cells are infected with the recom-
binant AAV vector, selected in MPA, and resistant colonies
are screened by pooling and PCR to identify correctly
targeted clones as described [13–15].
Once targeted clones are identified and single cell
cloned to ensure homogeneity of the starting population,
cells are plated in the presence of both MPA and a second
IMPDH inhibitor mizoribine. Mizoribine inhibits both
human cellular IMPDH and E. coli IMPDH with similar
potency. We reasoned that increased IMPDH expression
from gene amplification might cause resistance to
mizoribine, whereas the presence of MPA would continue
to inhibit endogenous IMPDH, even if amplified. Much
evidence points to DNA breakage as an initiating event in
the amplification process. Our strategy relies on sponta-
neous DNA breakage somewhere near our inserted IMPDH
cassette, perhaps aided by exposure of single-stranded
DNA due to depletion of nucleotide pools and stalling of
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DNA replication. The extent of amplification of the tar-
geted locus and surrounding loci would depend on where
these breaks occur, how well they are tolerated, and other
unknown factors that determine the extent of chromosome
amplifications, which are often highly variable in terms of
size and complexity.
Targeted amplification of 8p11-12 in human breast
cancer cells
As a proof of principle, we attempted to engineer ampli-
fication of the 8p11-12 region in the human breast cancer
cell line MCF-7. Amplification of 8p11-12 occurs in
approximately 15 % of human breast cancers, predomi-
nantly of the estrogen receptor positive subtype, of which
MCF-7 is representative [19, 20]. This amplification event
harbors multiple sub-regions of amplification, and various
investigators have identified oncogenic functions for nearly
a dozen candidate driver genes in the region using tradi-
tional overexpression or loss of function approaches
[21–26]. We reasoned that our experimental approach
might serve as a method to simultaneously amplify and
overexpress multiple genes in an amplicon, which is dif-
ficult to perform with traditional transgene methods. Fur-
thermore, transgenes do not recapitulate transcriptional
regulation of the genes from their endogenous promoter
and enhancer elements. MCF-7 does have copy number
abnormalities, which shows that at some point in its
transformation to cancer, it was capable of endogenous
chromosomal amplification. MCF-7 does not have ampli-
fication of chromosome 8p, however. In addition, MCF-7
cells were shown to amplify the DHFR locus in vitro in
response to methotrexate selection [5]. This is important as
the genetic basis for amplification remains obscure,
although presumably certain deficits in DNA repair,
replication, or cell cycle checkpoints are required to permit
amplifications to occur.
We designed homology arms to target the E. coli
IMPDH cassette to the 30 UTR of the ZNF703 gene, which
is at the telomeric end of the core 8p11-12 amplicon
(Fig. 1). Multiple targeted clones were identified by PCR
screening and purified to homogeneity by limiting dilution.
We next plated one of the targeted clones, named 38C-3, in
mizoribine. We identified three colonies resistant to 10 lM
mizoribine, designated as E8, F3, and G5. We initially
tested these colonies for increased copy number of the
targeted ZNF703 locus by performing qPCR with primers
specific to the targeting cassette and to the ZNF703 locus
outside of the region of the homology arms (data not
shown). Subsequently, we used droplet digital PCR to more
precisely measure copy number at the ZNF703 locus using
primers and a probe located near exon 1, normalized to the
RPP30 gene, of which MCF-7 has two copies. As shown in
Fig. 2, clones E8, F3, and G5 showed average ZNF703
copy number increases of approximately 2.5-fold relative
to parental MCF-7 and the targeted clone 38C-3 before
mizoribine selection. This indicates that the ZNF703
amplification occurred during mizoribine selection and was
not present in the targeted 38C-3 clone prior to selection.
To determine the extent and pattern of amplification, we
performed genome-wide array CGH on the pre-amplified
cells and amplified subclones (Fig. 3 and Supplemental
Figures 1–3). As expected from the ddPCR result, all three
subclones showed increased copy number of the ZNF703
PA5′ ARM 3′ ARMIRES IMPDH
ZNF703 ERLIN2






Fig. 1 AAV gene targeting strategy for engineering chromosomal
amplifications. 50 and 30 homology arms (orange) flank a selection
cassette containing an internal ribosome entry site (IRES, blue), the
E. coli IMPDH gene (green), and a polyadenylation signal (PA,
black). Targeting to the 30 UTR of the gene of interest is selected for
with mycophenolic acid (MPA) and identified by PCR screening.
Subsequent selection with mizoribine leads to pressure to amplify the
targeted cassette and flanking genes. Both exons of ZNF703 are
depicted, but ERLIN2 is shown schematically as a single exon, and
other genes are not shown
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locus. However, all three clones showed unique patterns of
copy number change at surrounding loci. Clones F3 and G5
showed broad, homogeneous amplification (much longer in
extent in F3) with concomitant copy number loss telomeric
to the amplification. This pattern of amplification with
distal loss is frequently observed in breast cancers on 8p
[19]. Clone E8 showed a different pattern of amplification
involving almost the entire 8p chromosome arm. Focal
regions of copy number gain were interspersed with normal
copy number in a sawtooth pattern, which has also been
commonly observed in human tumors. Thus, these exper-
imentally engineered multi-gene amplifications recapitu-
late several of the features of amplifications from actual
human tumors. Importantly, the amplified subclones did
MCF-7 38C-3 E8 F3 G5
Fig. 2 Droplet digital PCR measurement of copy number at the
ZNF703 locus at 8p12. Copy number is normalized to the two copy
RPP30 locus. From left to right, parental MCF-7 cells, a targeted
clone (38C-3) before mizoribine amplification selection, and three
amplified subclones of the 38C-3-targeted clone (E8, F3, G5). Bars

































Fig. 3 Copy number profile of chromosome 8 by array CGH. From
top to bottom, MCF-7, the targeted, non-amplified MCF-7 clone 38C-
3, and the mizoribine-amplified clones E8, F3, and G5. The y-axis
represents log2 ratios of copy number, with 0 representing diploid
copy number. Red boxes copy number gain, Green boxes copy
number loss. The ZNF703 locus is indicated by an arrow. Copy
number profiles did not differ from parental MCF-7 cells for the
remaining chromosomes (not shown)
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not differ from parental MCF-7 or pre-amplified 38C-3
cells on the long arm of chromosome 8 (where MCF-7 has
existing copy number gains, Fig. 3) or on the other chro-
mosomes (not shown). This indicates that the induced copy
number changes are specific and that the drug treatment
does not select for generalized chromosomal instability.
Because ddPCR and array CGH average copy number
over the entire population, we performed FISH to assess
copy number changes at the level of individual cells, using
probes for centromeric sequences on chromosome 8 and
three BAC probes located near FGFR1, at the centromeric
end of the 8p11-12 amplification, ZNF703, and NRG1,
which is located 5 Mb telomeric to ZNF703. Parental
MCF-7, 38C-3, and amplified subclones all showed two
signals for centromere 8, and MCF-7 and 38C-3 were
diploid for the other loci tested (Fig. 4 and Supplemental
Figure 4). Clones E8, F3, and G5 all showed increased
FISH signals for ZNF703, consistent with the estimated
copy number by ddPCR, and F3 and G5 showed similar
increases in signals for FGFR1. Clone E8 showed low level
gain of FGFR1, also consistent with the array CGH results
(Supplemental Figures 1 and 4). Clone G5 showed only a
single copy of NRG1 by FISH, consistent with the telom-
eric copy number loss observed by array CGH (Supple-
mental Figures 3 and 4). Clone E8 showed more
heterogeneity than clones F3 and G5 at the cellular level,
with significant variability of NRG1 copy number among
individual cells, possibly indicating a greater degree of
genomic instability in this clone (Supplemental Figure 4).
Copy number variation is a leading cause of gene
expression variation among tumors, and copy number-as-
sociated overexpression can be used as a criterion to
narrow down the list of candidate driver genes in a given
region. We performed qRT-PCR for genes in the core
8p11-12 amplification in our experimentally amplified
clones (Fig. 5). All clones showed increased expression of
ZNF703, as would be predicted; however, the clones dif-
fered in the extent and degree of copy number-associated
overexpression of neighboring genes in the region. Clone
G5 showed the highest relative expression in the greatest
number of genes, followed by clone F3, and clone E8
exhibited more modest changes. This trend is in keeping
with the broader increase of copy number for these genes in
G5 and F3 versus E8 seen by array CGH. These differences
may also reflect epigenetic variation among the clones.
Indeed, the correlation between copy number gain and gene
overexpression in cancer-associated amplifications is
imperfect.
There have been few systematic investigations of
overexpression of amplified genes at the protein level,
although individual candidate genes have been studied and
documented, such as HER-2. We examined protein
expression for several of the genes in the region, compared
to parental non-amplified MCF-7 cells and the 8p11-12
amplified breast cancer cell line MDA-MB-134VI (Fig. 6).
We observed protein overexpression of full length FGFR1
or its proteolytically processed C-terminal fragments in
clones F3 and G5 [27]. These clones also overexpressed
RAB11FIP1, and F3 additionally overexpressed ASH2L.
Protein expression differences for ZNF703 were less dra-
matic, in keeping with the low level increase in mRNA. It
should be noted that the targeted IMPDH cassette is
translated from an IRES, allowing independent posttran-











Fig. 4 FISH on parental MCF-7 cells and amplified ZNF703-targeted
subclones E8, F3, and G5. Nuclei are stained with DAPI. The green
probe is to chromosome 8 centromeric sequences. a The red probe is a
BAC in the ZNF703 region on 8p11-12. b The red probe is a BAC in
the FGFR1 region
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amplification of a targeted locus can lead to overexpression
of regional genes at the protein level, even when direct
selection for the activity of these proteins is not applied.
Discussion
Wehave demonstrated the use of gene targeting technology to
engineer site-specific chromosomal amplifications in a human
breast cancer cell line. Amplifications observed represent the
diversity of such events typically observed in amplifications
found in primary human breast tumors, including varying
extent of the amplified region, broad homogeneous gain ver-
sus sawtooth pattern of copy number change, and concurrent
copynumber loss of telomeric sequences.Amplification led to
overexpression of some, but not all, amplified genes, as with
primary tumors. In some cases, amplified genes were over-
expressed at the protein level as well.
We anticipate that this strategy can be applied to
potentially any locus and can be extended to other cell
types. Although we used AAV for gene targeting, other
targeting approaches relying on homologous recombination
could be used, such as CRISPR-Cas9 or TALEN technol-
ogy. We also anticipate that other selection markers could
be employed. For example, we have performed some pre-
liminary experiments using the L22F DHFR mutant, which
is more resistant to methotrexate and can be used as a
dominantly amplifiable marker in the presence of intact
cellular DHFR [9, 28]. In practice, it is unlikely that any
single marker will be universally effective for all cell types,
since cells will differ in their reliance on specific enzymatic
pathways. Similarly, cells may become resistant to the
selection drug through mechanisms other than gene
amplification (as has been observed with methotrexate), so
experimental approaches will have to be individualized and
determined empirically.
The boundaries of the experimental amplifications are
determined by the sites of DNA breakage and subsequent
processes of replication, repair, and chromosome segrega-
tion. These forces are largely unknown and to some extent
‘‘random’’ from the experimenter’s point of view. How-
ever, we anticipate that our strategy could be modified by
engineering-specific-targeted double-strand breaks (for
example, by incorporating a SceI endonuclease sequence in
the targeting cassette or using CRISPR-Cas9) to attempt to
control the initiation of the amplification event.
Although much has been learned about the amplification
process, many unknowns remain. It would be of interest to
engineer a cancer-associated amplification in a non-trans-
formed cell to determine whether a specific amplification
as a primary oncogenic event is sufficient to cause cellular

















38C3 pre-amp E8 F3 G5
Fig. 5 Copy number-associated overexpression of co-amplified
genes on 8p11-12. Quantitative real-time RT-PCR for selected genes
in the 8p11-12 region in their genomic order (ZNF703, telomeric;
MYST3, centromeric). Expression for each gene is normalized to a
reference housekeeping gene, TBP. The expression level in the pre-
amplified 38C-3 clone is set at 1. The mean and standard deviation of
























Fig. 6 Proteins in the amplified region are overexpressed. Western
blot for selected proteins from the 8p11-12 region. Lane 1, MCF-7.
Lane 2, MDA-MB-134VI, a human breast cancer cell line with known
amplification of 8p11-12. Lane 3, the targeted, pre-amplified 38C-3
clone. Lanes 4–6, amplified subclones derived from 38C3. ZNF703,
FGFR1, RAB11FIP1, and ASH2L are encoded by genes on 8p11-12.
Asterisks indicate C-terminal proteolytic processed fragments of
FGFR1. Migration of molecular weight standards in kilodaltons is
indicated on the right
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‘‘normal’’ cells to amplify genomic loci since they typically
have few aberrations in DNA repair and cell cycle check-
point genes that are likely important for facilitating the
process [29]. Some studies have suggested that cells with
intact p53 will be resistant to experimental amplification
[30]. MCF-7 has wild-type p53 genes, but it has a number
of other genetic aberrations which may allow amplification
to occur despite intact p53. We believe that our system can
provide a useful experimental platform to dissect the role
of specific genes and exposures as modifiers of the
amplification process at specific loci in distinct cell types.
It is not uncommon for recurrent chromosomal ampli-
fications in common human cancers to harbor anywhere
from several to dozens of genes. For some of these
amplifications, including the 8p11-12 and 11q13 amplifi-
cations in breast cancer, multiple plausible driver genes
remain after correlating copy number and gene expression.
Some investigators have recognized the possibility that
multiple oncogenes may cooperatively drive oncogenesis
in such amplicons, although it is difficult to overexpress
more than two or three candidate genes in a cell by tradi-
tional methods. The approach presented here is a potential
experimental strategy to model such cooperativity in an
isogenic cellular background.
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